Marwah Medicine

Medicine, NEET PG, NExT, NExT Exam

The Future of Anti-Hypertensive Therapy Explained

Once in 6 Months Blood Pressure Injection: The Future of Anti-Hypertensive Therapy Explained High blood pressure affects millions of people in India — and nearly 1 in 4 adults lives with hypertension, many without knowing it. The real challenge is not just treatment, but taking medicines regularly. Now imagine controlling blood pressure with just two injections per year. A new investigational therapy called zilebesiran may make this possible. Let’s understand it in simple language — clinically relevant, exam-focused, and easy to remember.   Featured Snippet: What Is the Once-in-6-Months Blood Pressure Injection? The once-in-6-months blood pressure injection refers to zilebesiran, an investigational RNA-interference therapy that lowers blood pressure by reducing liver production of angiotensinogen, a key component of the RAAS pathway. A single subcutaneous injection may provide blood pressure control for up to 6 months. 🇮🇳 Why This Matters: Hypertension in India Around 25–30% of Indian adults have hypertension. Many remain undiagnosed or irregular with treatment. Poor medication adherence leads to stroke, heart failure, and kidney disease. This makes long-acting therapies extremely interesting for the future of cardiovascular care. Related reading: [Hypertension management guide] (internal link)   Really? A Once-in-6-Months Anti-Hypertensive Drug? Yes — and this is what makes zilebesiran unique. Unlike conventional drugs that block hormones after formation, this drug works at the gene expression level. Daily pills block RAAS… RNAi stops RAAS from being born.   Mechanism of Action of Zilebesiran Target Liver-produced angiotensinogen (AGT) Method RNA interference (gene silencing) Effect ↓ Angiotensinogen ↓ Angiotensin II formation ↓ Vasoconstriction ↓ Blood pressure This means the drug acts upstream in the RAAS pathway, creating prolonged suppression. Related reading: [RAAS system explained simply] (internal link) Why Only Twice a Year? RNA-interference molecules remain active inside cells for a long time. Because of prolonged intracellular action: One subcutaneous injection suppresses AGT production for ~6 months. Dosing becomes biannual instead of daily. This mirrors what happened in diabetes care when therapy shifted from daily insulin to weekly injections. Clinical Trial Evidence — KARDIA Trials Phase II Study Highlights Double-blind, placebo-controlled trial 672 patients with hypertension Average baseline SBP: 143 mm Hg Key Findings Significant reduction in systolic BP vs placebo Additional benefit on top of standard medications BP lowering sustained for up to 6 months after one dose In some studies, the effect was similar to adding another oral antihypertensive drug. Why Is This a Big Deal? Solves adherence problems: Many patients forget daily pills. Twice-yearly injections could transform compliance. Continuous blood pressure control: No missed doses means more stable BP. Potential use in high-risk patients: Especially those uncontrolled despite multiple medications.   Limitations (Important Clinical Perspective) Still investigational (not routine therapy yet) Long duration means limited dose adjustment Side effects, if any, may persist longer Expected to be costlier initially So no — this does NOT replace current BP medicines yet.   Frequently Asked Questions (FAQ) ❓ What is the once-in-6-months BP injection? It is zilebesiran, an investigational RNA-interference drug that lowers blood pressure by reducing angiotensinogen production in the liver. Is zilebesiran available in India? No. It is currently under clinical trials and not yet approved for routine use. How does it differ from ACE inhibitors or ARBs? ACE inhibitors block hormone action, whereas zilebesiran prevents hormone production upstream. Who may benefit in the future? Patients with poor medication compliance or resistant hypertension may benefit if approved. Is it better than regular tablets? Not necessarily — current drugs remain effective and affordable.   Quick Summary Box Feature Zilebesiran Type RNA interference therapy Target Hepatic angiotensinogen Route Subcutaneous injection Frequency Every 6 months Status Investigational (Phase III underway) Major Advantage Improved adherence   Conclusion Will this replace daily BP tablets? Not yet. But it may represent the next evolution of hypertension treatment — where technology helps solve the biggest real-world problem: patients forgetting medicines. The future of cardiovascular pharmacology is moving toward long-acting, precision-based therapies — and zilebesiran may be one of the first steps in that direction.   References World Health Organization (WHO) ICMR Hypertension Data American College of Cardiology (ACC) trial presentations  

Medical, NEET PG

Motor neuron disease and amyotrophic lateral sclerosis

In this post we’ll break down the major types of MNDs, compare their clinical features and highlight points crucial for competitive exams like NEET PG, INI-CET, and FMGE. Core issue is combination of UMN and LMN lesion findings coexistent in a same patient for ALS. Physicist Stephen hawking was the longest living survivor of this fatal disorder that ultimately causes demise due to diaphragmatic paralysis. As bonus tip learn differences between AIDP and CIDP in 2 minutes at the bottom of this article. Comparison of Major Motor Neuron Disease  Disease  UMN involvement  LMN involvement  Key features  Onset & Progression  Age of Onset  Prognosis  Amyotrophic lateral Sclerosis (ALS) √ √ Mixed signs: spasticity + fasciculations; bulbar signs common Gradual onset, relentless progression 40-70 years Fatal within 3-5 years ( respiratory failure) Primary Lateral Sclerosis  √ X Pure UMN signs: spasticity, hyperreflexia, Babinski sign: no fasciculations Very slow progression >50 years Relatively benign Progressive muscular Atrophy (PMA) X √ Pure LMN signs; muscle wasting, fasciculations, flaccid weakness Gradual 30-60 years Better than ALS but can evolve into ALS Spinal muscular Atrophy (SMA) X √ Symmetrical LMN weakness, hypotonia, tongue fasciculations (esp. in infants) Depends on type (infantile to adult) Infancy to adulthood Varies (SMA type I is fatal in infancy) Progressive Bulbar Palsy  √ (bulbar UMNs) √ (bulbar LMNs) Dysarthria, dysphagia, tongue atrophy, emotional lability Often progresses to ALS 40-70 years Poor Pseudobulbar Palsy  √ X Dysarthria, dysphagia, emotional lability, but no tongue wasting or fasciculations Often associated with bilateral stroked / MS Older adults Variable   Key Clinical Differences  ALS (Amyotrophic lateral sclerosis) Hallmark: Combination of UMN and LMN signs in multiple regions Buzzwords: Fasciculations + spasticity: tongue atrophy; split hand sign PLS (Primary Lateral Sclerosis)  Hallmark: Pure UMN involvement Clue: No Fasciculations or muscle wasting PMA ( Progressive Muscular Atrophy Hallmark: Pure LMN disease Buzzwords: Muscle atrophy, areflexia, fasciculations, no spasticity May progress to ALS over time. SMA (Spinal Muscular Atrophy)  Genetics: Autosomal recessive, SMN1 gene mutation Types: Type I (Werdnig-Hoffmann): Infantile, floppy baby, fatal in 1st year Type II: Childhood onset Type III: (Kugelberg-Welander): Adolescent / adult onset Type: IV: Adult form, mildest   Progressive Bulbar Palsy Vs Pseudobulbar Palsy  Feature  Progressive Bulbar  Pseudobulbar  Site CN IX – XII (LMN) UMN to bulbar nuclei Tongue Atrophy, fasciculations Small spastic, no atrophy Reflexes Absent gag reflex Exaggerated jaw jerk Emotional lability Present Present Association May be variant of ALS Often bilateral strokes /MS   Important Exam Points  Most common MND: ALS ALS Affects both UMN and LMN – a key distinguishing feature Fasciculations + spasticity: Think ALS Tongue fasciculations in infants: Think SMA type I No sensory involvement is typical in MNDs. Frontotemporal dementia may coexist with ALS (especially C9 or F72 mutation) Riluzole is the only FDA – approval drug for ALS – prolongs survival by ~3 months. Recent Advances  Risdiplam for SMA Type: Oral SMN2 splicing modifier Mechanism: Increases production of functional SMN protein via enhanced SMN2 splicing Route: Oral syrup taken daily Age: Approved for infants (>2 months), children, and adult Gene therapy for SMA (Type I) with nusinersen and onasemnogene abeparvovec has revolutionized prognosis in children. Edaravone has been added as a treatment option in some ALS cases.   Bonus Tip  Comparison: AIDP vs CIDP Feature AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) CIDP (chronic Inflammatory Demyelinating Polyradiculoneuropathy)  Full form  Acute inflammatory demyelinating polyradiculoneuropathy Chronic Inflammatory Demyelinating Polyradiculoneuropathy Type  Most common variant of GBS Chronic form Onset Acute (subtype of GBS) Chronic (≥ weeks) Progression  Rapid (Similar to GBS) Slowly progressive or relapsing Weakness Ascending symmetric Similar but slower, often proximal and distal Reflexes  Absent or decreased Absent or decreased CSF Same as GBS Same ( mildly elevated protein, low WBC) Nerve Conduction  Demyelinating Demyelinating Treatment  IVIG or plasmapheresis Steroids IVIG, plasmapheresis (long -term)  

Medical, NEET PG

Irritable bowel Syndrome (IBS): A Practical Guide for Clinicians

Irritable Bowel Syndrome (IBS) is one of the most common functional gastrointestinal disorders encountered in clinical practice, yet it remains a diagnosis of exclusion and often misunderstood. It affects 10-15% of the global population, disproportionately impacting quality of life while posing a diagnostic challenge due to symptom overlap with inflammatory bowel disease (IBD). In this post, we’ll explore the pathophysiology, clinical features, diagnosis, and treatment of IBS with a special focus on dietary interventions (FODMAPs) and pharmacological options for IBS-C (constipation – predominant) and IBS-D (diarrhea- predominant) variants. We’ll also clarify key differences between IBS and IBD, a common source of confusion in clinical settings. What is IBS? IBS is chronic functional GI disorder characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of any identifiable structural or biochemical cause. Rome IV Criteria: Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with ≥ of the following: Related to defection Change in frequency of stool Change in form (appearance) of stool How to asses appearance of stool? Use Bristol stool chart as shown below Symptom onset must be at least 6 months before diagnosis. IBS vs IBD: A common Confusion Feature IBS IBD (Crohn’s /Ulcerative Colitis)   Nature Functional disorder Organic, inflammatory disease Pathology No mucosal inflammation or ulcers Mucosal inflammation, ulceration Colonoscopy Normal Abnormal (ulcers, erythema, pseudo-polyps) Histology Normal Inflammatory infiltrates, granulomas CRP/Fecal Calprotectin Normal Elevated Red flag signs Absent May have blood in stool, weight loss Risk of colon cancer No increased risk Increased risk   Clinical pearl: Always rule out IBD, colorectal cancer, and celiac disease before labeling a patient with IBS – especially in patients >50 or with alarming symptoms like weight loss, rectal bleeding or nocturnal symptoms. Pathophysiology of IBS IBS is multifactorial and still not fully understood. Key contributing factors include: Visceral hypersensitivity Altered gut motility Gut-brain axis dysfunction Post – infectious changes Microbiota alterations Psychological stressors ( anxiety / depression) Role of Diet: FODMAPs Explained Many patients with IBS report food -related triggers. The low FODMAP Diet is a central dietary intervention. What are FODMAPs? FODMAP= Fermentable Oligosaccharides, Disaccharides, Monosacchrides, and Polyols. These are short chain carbohydrates poorly absorbed in the gut and rapidly fermented by colonic bacteria, causing bloating, gas, and diarrhea. High FODMAP foods: Oligosaccharides: Wheat, rye, onions, garlic Disaccharides: Milk, yogurt (lactose) Monosaccharide: Apples, Honey (excess fructose) Polyols: Sorbitol, mannitol (found in artificial sweeteners, some fruits) Approach: Elimination phase: 4-6 weeks of low FODMAP intake Rechallenge phase: Gradual reintroduction to identify specific triggers Maintenance phase: Personalized, less restrictive diet Evidence supports the low FODMAP diet in reducing global IBS symptoms, particularly bloating and abdominal pain. Pharmacological Management Tailored according to predominant symptoms: IBS – C (Constipation – Predominant) Drug/ Class Mechanism Notes Fiber (e.g. psyllium) Bulking agent Soluble fiber preferred over insoluble PEG (Polyethylene glycol) Osmotic laxative First- line for many patients Lubiprostone Chloride channel activator (CIC-2) Increases intestinal fluid secretion Linaclotide Guanylate cyclase – C agonist Enhances fluid secretion and motility Prucalopride 5-HT4 receptor agonist Promotility agent; used selectively   Pro tip: Avoid stimulant laxatives long-term duet to potential for tolerance and cathartic colon. IBS – D (Diarrhea- Predominant) Drug/ Class Mechanism Notes Loperamide µ-opioid receptor agonist Symptomatic relief only; does not relieve pain Alosetron 5-HT3 antagonist Used in woman with severe IBS-D; rare ischemic colitis risk Rifaximin Non-absorbable antibiotic Useful in IBS-D with bloating; 2-week course Bile acid sequestrants Binds bile acids (e.g. cholestyramine) For patients with bile acid malabsorption Eluxadoline Mixed opioid receptor modulator Avoid in patients without gallbladder or with pancreatitis risk   For pain and global symptoms Drug/ Class Role Antispasmodics Relieve abdominal cramps (e.g. dicyclomine, hyoscine) Tricyclic Antidepressants (TCAs) Modulate pain and motility (e.g. amitriptyline) SSRIs/SNRIs For patients with predominant anxiety or depression Cognitive Behavioral Therapy (CBT) Especially effective in refractory cases   Red Flag Symptoms (NOT typically of IBS) Always investigate further if any of these are present: Age >50 with new onset symptoms Nocturnal diarrhea Unintentional weight loss Rectal bleeding Iron – deficiency anemia Family history of colorectal cancer or IBD   Summary Table: IBS subtypes and management Subtype Key Features First – line Management IBS-C Pain + infrequent, hard stools Fiber, PEG, linaclotide IBS- D Pain +frequent, loose stools Loperamide, rifaximin IBS- M Mixed symptoms Symptom – directed approach IBS-U Unclassified Supportive, individualized   “The art of IBS management is not in curing, but in relieving symptoms, validating patient concerns, and enhancing quality of life.”

INICET, Medical, Medicine classes, NEET PG

Hypokalemic vs. Hyperkalemic periodic paralysis – High Yield NEET PG & INI – CET guide

Why This Topic is Important for NEET PG & INI-CET Periodic paralysis disorders are commonly tested in NEET PG and INI-CET. A solid grasp of hypokalemic and hyperkalemic periodic paralysis will help in answering questions correctly. These conditions involve ion channel activity  affecting muscle function, leading to temporary paralysis. Let’s break it down in a high-yield, exam -focused manner. What is periodic paralysis? Periodic paralysis refers to rare neuromuscular disorders characterized by episodes of muscle weakness or paralysis triggered by fluctuation in serum potassium levels.  The two main types are mentioned in the tabular format highlighting key differences. Mnemonic to remember “HYPO has HIGH triggers, HYPER has Low Triggers” HYPO Kalemic Paralysis = HIGH Sugar & Carb intake causes an attack . HYPER Kalemic paralysis = LOW Food intake (Fasting) triggers the episode. Key differences – High – Yield Table Feature Hypokalemic Periodic Paralysis Hyperkalemic Periodic paralysis Cause Mutation in CACNA1S/SCN4A gene Primary answer as calcium channel defect Mutation in SCN4A gene Primary answer as sodium channel defect Serum potassium during attack Low (<3.5 mEq/L) High (>5.0 mEq/L) Triggers High -carb meals, exercise, stress Fasting, rest after exercise Onset Teenage years (10-20 years) Early childhood Duration of Attack Hours to days Minutes to hours Reflexes Reduced Normal Treatment Potassium supplementation, avoiding triggers Glucose, diuretics (thiazides)   Clinical cases to remember Hypokalemic Periodic Paralysis Hyperkalemic Periodic Paralysis A 15-year-old male wakes up with sudden muscle weakness after eating a large pizza and soda the previous night Blood tests show low serum potassium ( 2.5 mEq/L) A 6-year-old child experiences muscle weakness after skipping breakfast. Symptoms resolve spontaneously after a few hours. Blood tests show elevated potassium ( 5.6 mEq/L).   Diagnosis & Investigations Serum potassium levels during an attack Electromyography (EMG): Shows myotonic discharges in Hyper PP Genetic testing: Confirms mutations in SCN4A (Hyper PP) and CACNA1S/SCN4A (Hypo PP) Exercise Test: Potassium levels drop in Hypo PP and rise in Hyper PP   Treatment Approach – High Yield Table Condition Acute attack Management Long-Term prevention Hypokalemic PP Oral /IV potassium Avoid high-carb meals, Acetazolamide Hyperkalemic PP Glucose + insulin, diuretics Low potassium, diet, acetazolamide   Exam Pearls – Must – Know for NEET PG & INI- CET Hypokalemic PP is often linked to thyrotoxic periodic paralysis – commonly seen in Asian populations. Hyperkalemic PP is associated with myotonia (delayed muscle relaxation after contraction). Acetazolamide is used in both conditions as it stabilizes ion channels but can worsen type 2 RTA.   📌Related High – Yield Topics to Read click on this link https://marwahmedicine.com/newsite/blogs/ Suggested reading for doctors sitting for NEET PG and INICET examination from these blog posts 📌Barrter vs. Gitelman syndrome 📌 Renal Tubular Acidosis 📌 Electrolyte disorders – Quick Mnemonics& Cases

INICET, Medical, NEET PG

EPILEPSY

If you are looking for a quick reference table for all types of epilepsy, clinical features, EEG findings and First line drug this is the post that you have to save to your device.  This is followed by a video tutorial and then 5 MCQ with long options mimicking what happens in entrance exams like NEET PG and INICET examinations. Types of Epilepsy Types of Epilepsy Cause Clinical presentation EEG findings Drug of Choice (DOC) Generalized Tonic clonic Seizure (GTCS) Often idiopathic or genetic Sudden LOC followed by Tonic stiffening clonic jerks Postictal confusion Generalized high amplitude poly-spike & slow waves Valproate (Alt: Lamotrigine, levetiracetam) Absence Seizure Idiopathic (childhood onset) Brief staring spells, no postictal confusion, may be frequent Classic 3 Hz spike-and -wave discharges, generalized and symmetrical Ethosuximide (Alt; valproate ) Myoclonic Seizure Juvenile Myoclonic Epilepsy Sudden brief jerks, often in morning; preserved awareness 4-6 Hz polyspike and wave discharges Valproate (Alt; Levetiracetam) Atonic Seizure Often part of Lennox – Gastuat syndrome Sudden loss of muscle tone → falls (“drop attacks”) Slow spike-and -wave complex <2.5 Hz Valproate (Alt: Rufinamide, clobazam) Infantile Spasms West syndrome (TS, hypoxia, infections) Clusters of sudden flexor/extensor spasms; developmental delay Hypsarrhythmia; chaotic high -voltage slow waves & spikes ACTH (1st line) (Alt:vigobatrin if Tuberous sclerosis) Focal Seizure without impaired awareness Cortical lesion, trauma, stroke, infection Motor/sensory symptoms without impaired consciousness Focal spikes or sharp waves at seizures focus Carbamazepine (Alt: oxcarbazepine) Focal seizure with impaired awareness Same as above Aura →impaired consciousness→ automatisms (e.g. lip smacking) Interictal temporal spikes/sharp waves Carbamazepine Alt: Lamotrigine) Status Epilepticus Non – compliance, metabolic, trauma Seizure lasting > 5 min or repeated without recovery Continuous epileptiform activity or periodic discharges Lorazepam (acute) followed by IV Phenytoin drip or IV Valproate   Now you can go practical aspects and watch simulation from the following videos. This will help you understand the nuances of this table relatively better. https://www.youtube.com/watch?v=s4rxG1Ho8L8   Here are 5 NEET PG/INI-CET–style clinical questions on Epilepsy, with long and tricky options, followed by correct answers and brief explanations: Question 1 A 25-year-old male presents with a history of recurrent seizures characterized by sudden behavioral arrest, lip-smacking, and fumbling movements of the hands lasting about 1–2 minutes, followed by confusion and disorientation. MRI reveals hippocampal sclerosis. Which of the following is the most appropriate treatment option for long-term management? A. Continue valproate and phenytoin combination therapy with periodic dose adjustments and monitor for hepatic and hematologic toxicity B. Add clobazam to ongoing carbamazepine therapy to achieve better seizure control without planning for surgical options C. Refer for anterior temporal lobectomy after appropriate video EEG and neuroimaging evaluation, as drug resistance is likely D. Switch to levetiracetam monotherapy and monitor response for 12 months before considering invasive procedures Correct Answer: C. Refer for anterior temporal lobectomy after appropriate video EEG and neuroimaging evaluation, as drug resistance is likely Explanation: The patient has features of mesial temporal lobe epilepsy (MTLE), likely drug-resistant, especially with hippocampal sclerosis. Surgery (anterior temporal lobectomy) is the treatment of choice in refractory cases. Question 2 A 7-year-old child is brought to the clinic with a history of frequent brief episodes where she stops talking, stares into space for a few seconds, and then resumes activity as if nothing happened. EEG shows 3 Hz spike-and-wave discharges. Which of the following is the most appropriate first-line treatment? A. Carbamazepine, which is highly effective for generalized and focal seizures including absence B. Phenytoin, as it has broad-spectrum activity with minimal behavioral side effects in children C. Ethosuximide, as it is particularly effective for absence seizures and well tolerated D. Lamotrigine, which is preferred over valproate due to its favorable safety profile in young children Correct Answer: C. Ethosuximide, as it is particularly effective for absence seizures and well tolerated Explanation: Typical absence seizures respond best to ethosuximide. Valproate is also effective but used when generalized seizures coexist. Carbamazepine can worsen absence seizures.  Question 3 A 60-year-old male with a history of focal seizures develops a generalized tonic-clonic seizure in the emergency department that continues for over 5 minutes without regaining consciousness. IV access is available. What is the next best step in management? A. Administer IV phenytoin loading dose and wait 20 minutes before considering benzodiazepines Immediate administration of IV lorazepam followed by IV phenytoin to abort status epilepticus C. Secure airway and give IV mannitol before starting anti-epileptic treatment to prevent raised ICP D. Administer oral levetiracetam through nasogastric tube if IV lorazepam is unavailable  Correct Answer: B. Immediate administration of IV lorazepam followed by IV phenytoin to abort status epilepticus Explanation: Generalized convulsive status epilepticus (GCSE) requires benzodiazepines first (IV lorazepam), followed by a long-acting agent like phenytoin or valproate. Question 4 A 30-year-old woman with epilepsy is planning pregnancy. She is currently on valproate monotherapy with good seizure control. What is the best strategy in this case? A. Continue valproate and add folic acid 5 mg/day to reduce neural tube defect risk B. Switch to lamotrigine before conception as it has a lower teratogenic risk and is effective C. Stop all antiepileptic drugs before conception and monitor EEG to reduce fetal risk D. Add carbamazepine to valproate to lower the required dose of each and minimize side effects Correct Answer: B. Switch to lamotrigine before conception as it has a lower teratogenic risk and is effective Explanation: Valproate is highly teratogenic, especially causing neural tube defects. Lamotrigine is safer in pregnancy. Ideally, switch medications before conception.  Question 5 A 17-year-old male presents with early morning myoclonic jerks, especially soon after waking, and occasional generalized tonic-clonic seizures. He has no focal neurological deficits, and EEG shows generalized polyspike-and-wave discharges. Which of the following is the most likely diagnosis? A. Juvenile myoclonic epilepsy, a generalized epilepsy syndrome with excellent prognosis and good response to valproate B. Lennox-Gastaut syndrome, a severe childhood-onset epilepsy with tonic seizures, cognitive decline, and poor prognosis C. Benign rolandic epilepsy, a childhood epilepsy with focal seizures involving the face and normal development D. […]

INICET, NEET PG

Serum Albumin Ascites Gradient

SAAG value assessment is a common topic asked in NEET PG and INICET. Here is a quick table to remember causes of high SAAG ascites > 1.1 gm / dl . most of the time the question will be on early or late Budd Chiari syndrome. Go crush this in next 30 seconds. Mnemonic: CHIMP  

INICET, NEET PG, NEET PG 2025

Triple therapy in respiratory system: Must Know for NEET PG and INICET aspirants

Triple therapy term is used in management of pulmonary artery hypertension, COPD and cystic fibrosis. Let us now read in next 2 minutes a quick recap of this must asked topic for your forthcoming competitive examinations. Triple Therapy for Pulmonary Arterial Hypertension (PAH) Endothelin Receptor Antagonists (ERAs) Example: Bosentan, Ambrisentan, Macitentan Action: Blocks endothelin, a vasoconstrictor, to reduce pulmonary vascular resistance. Phosphodiesterase-5 (PDE-5) Inhibitors or Soluble Guanylate Cyclase (sGC) Stimulators Example (PDE-5): Sildenafil, Tadalafil Example (sGC stimulator): Riociguat Action: Increases nitric oxide (NO) signaling to promote vasodilation. Prostacyclin Analogues or Prostacyclin Receptor Agonists Example: Epoprostenol, Treprostinil, Selexipag Action: Mimics prostacyclin to dilate blood vessels and inhibit platelet aggregation. This combination targets multiple pathways involved in PAH pathophysiology, offering better control of the disease. Triple Therapy for COPD Triple therapy for Chronic Obstructive Pulmonary Disease (COPD) involves a combination of inhaled medications to manage symptoms and reduce exacerbations. Long-Acting Beta-2 Agonists (LABA) Example: Salmeterol, Formoterol, Indacaterol Action: Broncho dilates airways for symptom relief and improved airflow. Long-Acting Muscarinic Antagonists (LAMA) Example: Tiotropium, Glycopyrrolate, Umeclidinium Action: Reduces bronchoconstriction by blocking muscarinic receptors in the airways. Inhaled Corticosteroids (ICS) Example: Budesonide, Fluticasone, Beclomethasone Action: Reduces airway inflammation and frequency of exacerbations. Triple therapy (LABA + LAMA + ICS) is recommended for patients with moderate to severe COPD who have frequent exacerbations despite dual therapy. Triple Therapy for Cystic Fibrosis (CF) For patients with Cystic Fibrosis, triple therapy specifically refers to the combination of CFTR modulators targeting different aspects of the CFTR protein defect (commonly associated with the F508del mutation). Elexacaftor Action: Facilitates the movement of defective CFTR protein to the cell surface. Tezacaftor Action: Improves CFTR protein processing and stability. Ivacaftor Action: Potentiates the function of the CFTR protein at the cell surface, enhancing chloride ion transport. This combination therapy significantly improves lung function and quality of life in CF patients with the F508del mutation. For more insightful information keep this page bookmarked. You can also check out this link https://marwahmedicine.com/newsite/bartter-syndrome-vs-gitelman-syndrome-a-must-know-topic-for-neet-pg-ini-cet-aspirants/

INICET, NEET PG, NEET PG 2025

Bartter Syndrome vs. Gitelman Syndrome: A Must-Know Topic for NEET PG & INI-CET Aspirants

When preparing for NEET PG and INI-CET, mastering renal tubular disorders is crucial. Among these, Bartter Syndrome and Gitelman Syndrome are frequently tested due to their importance in clinical practice. Understanding their pathophysiology, clinical presentation, and lab findings with precision is essential for scoring high in medical entrance exams. Pathophysiology in a Nutshell Bartter Syndrome mimics the effect of chronic loop diuretics (e.g., furosemide), leading to salt-wasting and hypokalemia. Gitelman Syndrome mimics thiazide diuretics, causing hypokalemia, hypomagnesemia, and hypocalciuria. Clinical Case Example Case 1 Case 2 A 3-month-old infant presents with failure to thrive, polyuria, and hypokalaemia. Urinary calcium is high. Think Bartter Syndrome 15-year-old presents with muscle cramps, fatigue. Labs show hypokalaemia, hypomagnesemia and low urinary calcium. Think Gitelman Syndrome.   These clinical and biochemical differences should be memorized thoroughly to answer exam questions accurately. Bookmark this page on marwahMedicine.com for your last-minute revision!

INICET

MUST READ TOPICS FOR INICET EXAM

In the last week before the INICET, focusing on high-yield, often-tested topics can maximize your efficiency. Here’s a prioritized list to help with revision of must do 12 subjects that can be revised in last few days before the exam. Anatomy Head and Neck: Cranial nerves (especially VII, IX, X), triangles of the neck, pharyngeal arches, eye muscles including palsy of nerves. Neuroanatomy: Spinal tracts, brainstem nuclei, cerebellar pathways, stroke syndromes like Foville syndrome vs Millard Gubler syndrome, Medial medullary syndrome vs Lateral medullary syndrome Thorax: Mediastinum, heart anatomy (chambers, valves), lung segments Abdomen and Pelvis: Blood supply, nerve supply, lymphatics, major muscles Embryology: Common congenital anomalies and their developmental basis   Quick Tips for the Last Week:   Physiology Cardiovascular:  Cardiac cycle including JVP and heart sound correlation, ECG basics, hemodynamics. Respiratory: Mechanics of breathing, oxygen and CO₂ transport Renal: Glomerular filtration, acid-base balance. Endocrinology: Pituitary, thyroid, adrenal hormones, and their regulation. Neurophysiology: Nerve conduction, reflexes, sensory pathways. Biochemistry Metabolic Pathways: Glycolysis, TCA cycle, urea cycle, and key regulatory enzymes. Molecular Biology: DNA/RNA structure, replication, transcription, translation. Vitamins and Minerals: Deficiency symptoms and biochemical roles. Genetics: Inheritance patterns, common genetic disorders, molecular techniques. Pharmacology Antimicrobials: Mechanisms of action, major side effects, common resistances. Cardiovascular Drugs: Anti-hypertensives, anti-arrhythmics, and common side effects. Central Nervous System: Antipsychotics, antidepressants, and antiepileptics. Endocrine Pharmacology: Insulin, oral hypoglycemics, and thyroid medications. Autonomic Nervous System: Sympathomimetics, parasympatholytics, cholinergics.      5.Pathology Cell Injury and Adaptation: Apoptosis, necrosis, cellular responses. Inflammation and Repair: Acute and chronic inflammation, wound healing. Neoplasia: Tumor classification, hallmarks of cancer, oncogenes. Systemic Pathology: Important diseases of each system with key features. Hematology: Anemias, leukemias, clotting disorders. Microbiology Bacteriology: Gram-positive vs. Gram-negative, important bacteria (e.g., Staph, Strep, E. coli). Virology: DNA vs. RNA viruses, diseases caused by common viruses. Parasitology: Malaria, helminths, protozoa. Immunology: Hypersensitivity reactions, autoimmune diseases, vaccines. Forensic Medicine Injuries and Wounds: Types of wounds, legal aspects. Poisons: Common poisons, antidotes, clinical features. Medical Jurisprudence: Consent, negligence, legal responsibilities of doctors. Community Medicine Epidemiology: Study designs, measures of association. Biostatistics: Mean, median, mode, sensitivity, specificity. National Health Programs: Focus on major programs like RNTCP, NACP, immunization. Preventive Medicine: Screening, vaccination schedules, levels of prevention. Medicine Cardiology: Heart failure, arrhythmias, valvular diseases. Pulmonology: COPD, asthma, tuberculosis. Neurology: Stroke, epilepsy, movement disorders. Endocrinology: Diabetes mellitus, thyroid disorders. Gastroenterology: Liver diseases, pancreatitis, malabsorption. Surgery Trauma: ATLS protocol, management of head injury, abdominal trauma. Abdomen: Hernias, appendicitis, intestinal obstructions. Thyroid and Breast: Common conditions like goiter, breast lumps. Vascular Surgery: Peripheral arterial disease, DVT. Orthopedics: Fracture types, bone healing, common pediatric conditions. Obstetrics and Gynecology Obstetrics: Normal labor, PPH, hypertensive disorders, antenatal care. Gynecology: Menstrual disorders, PCOS, fibroids. Reproductive Endocrinology: Infertility, contraception, menopause. Oncology: Cervical, breast, and ovarian cancers. Pediatrics Growth and Development: Milestones, growth charts. Neonatology: Newborn care, jaundice, respiratory distress. Infectious Diseases: Common pediatric infections, vaccine-preventable diseases. Nutrition: Breastfeeding, malnutrition. Staying calm and avoiding burnout is crucial. Take breaks, focus on weaknesses if any, and keep confidence high. Good luck!

FMGE, INICET, Medical, Medicine, NEET PG, NExT Exam

Must Read Topics in General Medicine for INICET Examination

The INICET tends to blend image-based questions with clinical vignettes, emphasizing practical application over rote learning. Clinical reasoning, such as interpreting lab values or recognizing syndromes from case scenarios, is prioritized. Also, several questions in the last few papers have integrated basic sciences like pathology and microbiology into clinical contexts, so revisiting integrated concepts may give you an edge. For the November INI-CET (Institute of National Importance Combined Entrance Test), General Medicine is a key subject. The exam tends to emphasize clinical knowledge, diagnostics, management protocols, and recent updates. Here’s a structured list of must-know topics for General Medicine preparation: Cardiology – ECG interpretation– MI, arrhythmias, heart blocks, electrolyte disturbances Horizontal ST depression with upright T waves + R/S > 1 in lead V2 HTN patient with SOB and palpitations. On examination, HR= 120 min, irregular with BP= 90/60 mm Hg. Bilateral crackles in both lung fields is seen. Which is not correct? a. Rate control with esmolol b. Warfarin is not used non -valvular atrial fibrillation c. Rhythm control with Amiodarone d. DC shock is not given in persistent AF a a,b b,c b,d – Brugada syndrome vs TTCM -Acute Coronary Syndrome (STEMI/NSTEMI management) – Congestive Heart Failure (CHF) and NYHA Classification – Infective Endocarditis (update ISCVD 2023 update modified Duke’s criteria) – Hypertension – Aortic dissection management based on type A and type B Neurology – Stroke – Types, NIHSS score, thrombolysis, secondary prevention Would you perform thrombolysis a patient with weakness of face and arm weakness for last 1 hour with normal CT scan – Epilepsy – types and GCSE management – Parkinson’s disease vs HD vs PSP – Multiple Sclerosis and Guillain-Barré Syndrome – Meningitis/Encephalitis – Empirical antibiotics, CSF findings – Headache – Migraine, cluster headache, tension headache vs SAH vs GCA Endocrinology – Diabetes Mellitus – Diagnostic criteria of DKA/HHS management – Thyroid Disorders – Hypo- and hyperthyroidism, nodules, malignancy markers – Adrenal Disorders – Addison’s disease, Cushing’s syndrome   – Pituitary Disorders – Acromegaly, SIADH, DI (diabetes insipidus) – MEN Syndrome Pulmonology – Sleep Apnea Syndrome and obesity hypoventilation syndrome – Pulmonary Embolism and DVT – Risk factors, anticoagulation therapy Biker had polytrauma and develops breathing difficulty after 12 hours of injury. Sp02= 85%CT chest is shown. Echo shows Normal cardiac parameters. a. Fat embolism b. Pulmonary embolism c. ARDS d. Pneumothorax – COPD and Asthma – Harrison based guidelines, stepwise management – Interstitial Lung Diseases (ILDs) and Sarcoidosis – Tuberculosis (including MDR-TB management) Gastroenterology and Hepatology – Chronic Liver Disease and Cirrhosis – Child-Pugh score, MELD – Hepatitis – B graphs of Acute and chronic hepatitis B – GI bleed – Upper vs. lower, endoscopic management – Boerrhave vs Stomach volvulus vs Mallory Weiss vs Acute variceal bleeding Nephrology – Acute interstitial nephritis: Eosinophiluria — CIN vs Athero-embolic kidney disease -Fluid and Electrolyte Disorders – Sodium, potassium, calcium disturbances – Acute Kidney Injury (AKI) vs Chronic Kidney Disease (CKD) identification – Glomerulonephritis – RPGN, nephrotic vs nephritic syndrome – Renal replacement therapy – Hemodialysis, CRRT, peritoneal dialysis Rheumatology – Overlap syndrome – Anti synthetase syndrome vs Dermatomyositis vs Polymyositis Systemic Lupus Erythematosus (SLE) – Diagnostic criteria and antibodies – Rheumatoid Arthritis – Treatment protocols (DMARDs, biologics) – Vasculitis syndromes – ANCA-associated vasculitis, Takayasu’s arteritis – Gout and Pseudogout Infectious Diseases – Scrub typhus – Tropical Infections – Dengue, Malaria – HIV/AIDS – ART guidelines, opportunistic infections – COVID-19 and Post-COVID Syndromes -Sepsis and Septic Shock – Management protocols Hematology and Oncology – Leukemia and Lymphoma – Acute vs chronic, Hodgkin’s vs non-Hodgkin’s – Multiple Myeloma and Plasma Cell Disorders – Coagulation Disorders – DIC, hemophilia, thrombophilia – Paraneoplastic Syndromes General Topics & Miscellaneous – Acid-Base Disorders (ABG interpretation) – Shock – Types and management Study Tips  – Solve MCQs from previous INI-CET papers and clinical vignettes. – Focus on latest guidelines and protocols– These are frequently tested. – Give time to integrated questions involving multi-system involvement (e.g., heart and kidney-related disorders). This plan covers high-yield topics that are essential for the exam. Practice application-based questions regularly and ensure you revise the core topics thoroughly.

Scroll to Top